|
DK1141028T3
(da)
|
1998-12-23 |
2010-05-25 |
Pfizer |
Humane monoklonale antistoffer til CTLA-4
|
|
EP1210428B1
(en)
|
1999-08-23 |
2015-03-18 |
Dana-Farber Cancer Institute, Inc. |
Pd-1, a receptor for b7-4, and uses therefor
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7163937B2
(en)
|
2003-08-21 |
2007-01-16 |
Bristol-Myers Squibb Company |
Cyclic derivatives as modulators of chemokine receptor activity
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
CA2647282A1
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
IN2012DN01719A
(https=)
*
|
2009-08-21 |
2015-06-05 |
First Solar Inc |
|
|
US8383812B2
(en)
|
2009-10-13 |
2013-02-26 |
Bristol-Myers Squibb Company |
N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
CA2828940C
(en)
|
2011-03-10 |
2024-04-16 |
Provectus Pharmaceuticals, Inc. |
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
HK1204557A1
(en)
|
2012-05-31 |
2015-11-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-l1
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3916017A1
(en)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1 antibodies
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
MA44594B1
(fr)
|
2015-05-29 |
2020-09-30 |
Memorial Sloan Kettering Cancer Center |
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
|
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
PH12017501857B1
(en)
*
|
2015-06-16 |
2024-01-17 |
Merck Patent Gmbh |
Pd-l1 antagonist combination treatments
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
|
KR102055396B1
(ko)
|
2015-08-11 |
2019-12-12 |
우시 바이올로직스 (케이만) 인코포레이티드 |
신규한 항-pd-1 항체
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
WO2017106150A2
(en)
*
|
2015-12-15 |
2017-06-22 |
The Procter & Gamble Company |
Leg gasketing cuff with tackifier-free adhesive
|
|
MX2018007295A
(es)
|
2016-01-11 |
2019-03-28 |
Armo Biosciences Inc |
Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
|
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
|
CN111491361B
(zh)
|
2016-02-02 |
2023-10-24 |
华为技术有限公司 |
确定发射功率的方法、用户设备和基站
|
|
WO2017165125A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
|
|
SMT202200088T1
(it)
*
|
2017-07-20 |
2022-03-21 |
Bristol Myers Squibb Co |
Procedimento per la preparazione di n-((1r,2s,sr)-5-(tert-butilammino)-2-((s)-3-(7-tert-butilpirazolo[1,5-a][1,3,5]triazin-4-ilammino)-2-ossopirrolidin-1-il)cicloesil)acetammide
|